Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating crucial clinical data in Fate Therapeutics鈥� dense SEC reports can feel like searching for a single nucleotide in a genome. Trial updates, cash-runway projections, even FDA feedback hide inside technical language that spans hundreds of pages. If you鈥檝e ever asked, 鈥淗ow do I read Fate Therapeutics鈥� 10-K?鈥� or 鈥淲here are Fate Therapeutics insider trading Form 4 transactions listed?鈥�, you know the challenge.
Stock Titan鈥檚 AI bridges that gap. Our platform delivers real-time alerts the moment a Fate Therapeutics quarterly earnings report 10-Q filing or an 8-K material event hits EDGAR. AI-powered summaries extract R&D spend, enrollment status, and partnership terms, offering Fate Therapeutics SEC filings explained simply. Click once to view Fate Therapeutics Form 4 insider transactions in real-time and spot executive stock transactions before the market reacts.
Each document is mapped to the questions investors actually ask: the annual report 10-K simplified shows cash burn and pipeline runway; the proxy statement executive compensation reveals milestone-based pay structures; 8-K material events explained highlight clinical holds or breakthrough-therapy designations; insider trading forms outline sentiment shifts. With our Fate Therapeutics earnings report filing analysis, you can compare sequential trial costs, monitor dilution risk, and evaluate strategic collaborations鈥攁ll without wading through biotech jargon. Start understanding Fate Therapeutetics SEC documents with AI today and turn complex disclosures into actionable insight.
comScore, Inc. (SCOR) 鈥� Form 4 insider filing
Director Matthew F. McLaughlin received an equity grant of 10,000 restricted stock units (RSUs) on 07/01/2025 under the company鈥檚 2018 Equity and Incentive Compensation Plan. Each RSU represents one share of common stock.
Vesting schedule: the award vests in full on the earliest of (i) the 2026 annual shareholder meeting, (ii) 30 June 2026, or (iii) a change-of-control event, subject to continued board service. Shares are delivered after separation from service or a change of control.
Compensation changes: the grant鈥檚 fair-value target is $120,000, calculated by dividing the target amount by a reference price of $12.00. This represents a significant reduction from the prior director compensation formula, which allocated $170,000 divided by the market price at grant (previously $5.07). The Board reduced overall compensation and applied a higher share price to more closely align directors鈥� incentives with long-term shareholder value.
Post-transaction ownership: McLaughlin now beneficially owns 10,000 derivative securities (RSUs) held directly; no non-derivative common shares were reported.
The filing is routine and involves no open-market transactions, cash outflow, or immediate dilution; it primarily signals a shift in board compensation structure rather than a material operational event.
Redmile Group, LLC, Jeremy C. Green and RedCo II Master Fund, L.P. have filed Amendment No. 9 to their Schedule 13D on Fate Therapeutics, Inc. (NASDAQ: FATE). The filing, triggered by an event dated 07 July 2025, updates the group鈥檚 ownership disclosure and key blocking provisions.
- Aggregate beneficial ownership: 17,941,579 common shares (direct and deemed) representing 14.9 % of FATE鈥檚 outstanding common stock (114,633,022 shares as of 6 May 2025).
- Key holder detail: RedCo II Master Fund holds 13,479,013 shares (11.3 %). All shares are subject to shared voting and dispositive power; no reporting person has sole power.
- Warrants & preferred stock: 鈥� Pre-Funded Warrants covering 3,691,324 shares (exercise price $0.001) 鈥� Class A Preferred Stock convertible 1-for-5 into up to 810,065 shares (RedCo II) and additional preferred shares across other Redmile funds.
Both instruments are governed by 14.99 % beneficial-ownership blockers. - Change in blocker threshold: On 1 July 2025 Redmile elected to raise the 鈥淢aximum Percentage鈥� under the Warrant Beneficial Ownership Blocker from 9.99 % to 14.99 % (effective 61 days later). This allows the group to exercise additional warrants and approach the new 14.99 % cap without breaching Section 13(d) limits.
- Funding source: Working capital of various Redmile-managed private investment funds (no external financing disclosed).
- Historical context: This is the ninth amendment to an initial 13D filed in 2018, reflecting the evolution of Redmile鈥檚 position and security mix (common, warrants, preferred, options, RSUs).
The amendment does not announce new purchases or sales but formalises the larger ownership cap, clarifies the composition of the beneficial stake, and reiterates blocker mechanics designed to limit ownership to 14.99 % of outstanding commons.
FAQ
What is the current stock price of Fate Therapeutic (FATE)?
What is the market cap of Fate Therapeutic (FATE)?
What is the primary focus of Fate Therapeutics?
How does Fate Therapeutics' technology differentiate it from other cell therapy companies?
What therapeutic areas are targeted by Fate Therapeutics' pipeline?
How does the company鈥檚 iPSC platform contribute to its product development?
What clinical advancements have been made by Fate Therapeutics?
How does Fate Therapeutics ensure product consistency and quality?
What are the benefits of off-the-shelf cell therapies developed by Fate Therapeutics?
How does Fate Therapeutics maintain scientific and regulatory rigor?
